Paul W. Maffuid Sells 38,054 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock
MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) EVP Paul W. Maffuid sold 38,054 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $0.92, for a total value of $35,009.68. Following the sale, the executive vice president now owns 283,703 shares of the company’s stock, valued at $261,006.76. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
MabVax Therapeutics Holdings, Inc. (MBVX) traded down $0.02 during trading hours on Friday, reaching $0.87. The company’s stock had a trading volume of 267,600 shares, compared to its average volume of 420,283. MabVax Therapeutics Holdings, Inc. has a 52 week low of $0.43 and a 52 week high of $3.57. The company has a current ratio of 0.54, a quick ratio of 0.54 and a debt-to-equity ratio of 0.80. The stock has a market cap of $19.90, a price-to-earnings ratio of -0.25 and a beta of 1.52.
MabVax Therapeutics (NASDAQ:MBVX) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.54) EPS for the quarter. analysts anticipate that MabVax Therapeutics Holdings, Inc. will post -3.01 earnings per share for the current year.
WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/paul-w-maffuid-sells-38054-shares-of-mabvax-therapeutics-holdings-inc-mbvx-stock/1814017.html.
About MabVax Therapeutics
MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.
Receive News & Ratings for MabVax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.